DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Latest Information Update: 19 Aug 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Adenoid cystic carcinoma; Adrenocortical carcinoma; Advanced breast cancer; Appendiceal cancer; Basal cell cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Chordoma; Choriocarcinoma; Colon cancer; Colorectal cancer; Endometrial cancer; Extramammary Paget disease; Fibroma; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Gastrointestinal stromal tumours; Gestational trophoblastic disease; Giant cell tumours; Haemangiosarcoma; Head and neck cancer; Laryngeal cancer; Lung cancer; Nerve sheath neoplasms; Neuroblastoma; Neuroendocrine tumours; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Paraganglioma; Parathyroid cancer; Pelvic cancer; Peritoneal cancer; Perivascular epithelioid cell tumours; Phaeochromocytoma; Pharyngeal neoplasms; Pituitary cancer; Prostate cancer; Rectal cancer; Renal cell carcinoma; Salivary gland cancer; Sarcoma; Seminoma; Solid tumours; Squamous cell cancer; Teratoma; Thyroid cancer; Tracheobronchial cancer; Trophoblastic tumour; Urogenital cancer; Vulvovaginal cancer
- Focus Therapeutic Use
- Acronyms DART
- 04 Jun 2024 Results (n=487) evaluating mixed response and survival outcomes among patients with various tumors receiving dual checkpoint therapy, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2024 Results assessing associations between immune-related adverse events observed in the first cycle (6 weeks) of therapy were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 13 Dec 2023 Planned End Date changed from 31 Oct 2024 to 1 May 2026.